Participants in the Breast Cancer Forum discussed improving therapeutic processes based on personalized medicine and adapting systemic solutions to changing therapeutic paradigms.
Without genetic diagnosis, it is difficult to design tailor-made treatment
Professor Renata Duchnowska, head of the Department of Oncology at the Military Medical Institute in Warsaw, pointed out the importance of multigene testing to help select the right treatment. Previously, treatment selection in hormone-dependent (luminal) HER2-negative breast cancer was based on clinicopathological factors, which did not always answer the question of how to select complementary therapy. - Multigene tests are not new, as they have been on the international market for many years. Unfortunately, in Poland they are still not reimbursed. There are already quite a few of them: Oncotype DX and MammaPrint, Breast Cancer Index or EndoPredict. All of them have prognostic value and tell you who to treat. Among them, Oncotype DX stands out, which is the only one that tells you how to treat- she stressed. She added that the effectiveness of Oncotype DX has been confirmed in two large clinical trials: TAILORx in patients without involved axillary lymph nodes and RxPONDER in women with involved 1-3 axillary lymph nodes.
Michal Jarzab, PhD, of the Center for Diagnosis and Treatment of Breast Diseases at the Maria Sklodowska-Curie National Cancer Institute - National Research Institute in Gliwice, Poland, spoke about the results of the PONDx study, published in the scientific journal Contemporary Oncology in October, which showed the impact of using the Oncotype DX multigene test on clinical decision-making. It was found to reduce the use of chemotherapy in patients with early HER2-negative/HR-positive breast cancer without lymph node involvement. ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
